Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Elan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Elan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Elan

2Q Revenues: $136.4 million (+15%)

2Q Loss: $90.5 million (loss of $142.6 million 2Q2005)

YTD Revenues: $270.7 million (+22%)

YTD Loss: $123.8 million (loss of $258.2 million YTD2005)

Comments: The net loss for the quarter was down 37%, primarily due to growth in product revenue and improved operating margins. R&D spending was down 18% to $52.6 million in the quarter. The company launched Tysabri in Germany, Ireland, UK and Sweden and re-introduced it in the U.S. in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters